Y Intercept (Hong Kong) LTD Biocryst Pharmaceuticals Inc Transaction History

Y Intercept (Hong Kong) LTD

$1.37 Billion
Q1 2025

A detailed history of Y Intercept (Hong Kong) LTD transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Y Intercept (Hong Kong) LTD holds 141,865 shares of BCRX stock, worth $1.5 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

141,865

Previous 68,623 106.73%

Holding current value

$1.5 Million

Previous $516,000 106.01%

% of portfolio

0.08%

Previous 0.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 05, 2025	BUY	$7.06 - $9.39 $517,088 - $687,742	73,242 Added 106.73%	141,865 $1.06 Million
Q4 2024 Feb 04, 2025	SELL	$7.03 - $8.43 $101,935 - $122,235	-14,500 Reduced 17.44%	68,623 $516,000
Q3 2024 Nov 15, 2024	SELL	$6.41 - $8.69 $39,927 - $54,130	-6,229 Reduced 6.97%	83,123 $631,000
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $369,023 - $606,700	89,352 New	89,352 $552,000
Q4 2022 Feb 14, 2023	SELL	$10.5 - $14.2 $306,873 - $415,009	-29,226 Closed	0 $0
Q3 2022 Feb 14, 2023	BUY	$10.79 - $14.81 $315,348 - $432,837	29,226 New	29,226 $368,000
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $127,645 - $218,189	-11,042 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $123,449 - $170,709	11,042 New	11,042 $153,000
Q3 2021 Nov 15, 2021	SELL	$14.21 - $17.65 $152,572 - $189,508	-10,737 Closed	0 $0
Q2 2021 Aug 26, 2021	BUY	$9.5 - $17.24 $102,001 - $185,105	10,737 New	10,737 $170,000
Q1 2021 May 12, 2021	SELL	$7.37 - $13.61 $92,707 - $171,200	-12,579 Closed	0 $0
Q4 2020 Feb 05, 2021	BUY	$3.37 - $8.61 $42,391 - $108,305	12,579 New	12,579 $94,000

Others Institutions Holding BCRX

# of Institutions

293

Shares Held

177M

Call Options Held

721K

Put Options Held

489K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.96B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.

Account

Y Intercept (Hong Kong) LTD Biocryst Pharmaceuticals Inc Transaction History